OTCPK:IGAP

Stock Analysis Report

Executive Summary

Integrity Applications, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Europe and the Asia Pacific.

Snowflake

Fundamentals

Imperfect balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Integrity Applications's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.2%

IGAP

1.9%

US Medical Equipment

0.5%

US Market


1 Year Return

-10.2%

IGAP

15.6%

US Medical Equipment

6.8%

US Market

Return vs Industry: IGAP underperformed the US Medical Equipment industry which returned 15.6% over the past year.

Return vs Market: IGAP underperformed the US Market which returned 6.8% over the past year.


Shareholder returns

IGAPIndustryMarket
7 Day-2.2%1.9%0.5%
30 Day-2.2%-2.1%-0.8%
90 Day120.0%-0.4%-0.9%
1 Year-10.2%-10.2%16.6%15.6%9.2%6.8%
3 Year-82.5%-82.5%72.2%67.0%45.6%36.2%
5 Year-92.7%-92.7%125.9%100.9%63.2%45.4%

Price Volatility Vs. Market

How volatile is Integrity Applications's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Integrity Applications undervalued compared to its fair value and its price relative to the market?

4680.85x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IGAP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IGAP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IGAP is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: IGAP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IGAP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IGAP is overvalued based on its PB Ratio (4680.9x) compared to the US Medical Equipment industry average (3.8x).


Next Steps

Future Growth

How is Integrity Applications forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Integrity Applications has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of IGAP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Integrity Applications's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Integrity Applications performed over the past 5 years?

-52.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IGAP is unprofitable, and losses have increased over the past 5 years at a rate of -52% per year.

Accelerating Growth: Unable to compare IGAP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IGAP is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: IGAP has a negative Return on Equity (-31435.43%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: IGAP is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IGAP is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Integrity Applications's financial position?


Financial Position Analysis

Short Term Liabilities: IGAP's short term assets ($2.5M) do not cover its short term liabilities ($2.6M)

Long Term Liabilities: IGAP's short term assets (2.5M) exceeds its long term liabilities (411.9K)


Debt to Equity History and Analysis

Debt Level: IGAP's debt to equity ratio (1177.2%) is considered high

Reducing Debt: IGAP had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: IGAP has a low level of unsold assets or inventory.

Debt Coverage by Assets: IGAP's debt is covered by short term assets (assets are 13.864390x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IGAP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IGAP has less than a year of cash runway if free cash flow continues to grow at historical rates of 10% each year.


Next Steps

Dividend

What is Integrity Applications's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IGAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IGAP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IGAP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IGAP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IGAP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Integrity Applications's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Integrity Applications has no CEO, or we have no data on them.


Management Age and Tenure

2.3yrs

Average Tenure

54yo

Average Age

Experienced Management: IGAP's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

2.6yrs

Average Tenure

65yo

Average Age

Experienced Board: IGAP's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jolie Kahn (54yo)

    Interim Chief Financial Officer

    • Tenure: 0.2yrs
  • Avner Gal (65yo)

    Co-Founder

    • Tenure: 2.6yrs
    • Compensation: US$187.39k
  • David Malka (54yo)

    Co-Founder & Executive VP of Operations

    • Tenure: 18.8yrs
    • Compensation: US$402.27k
  • Eugene Naidis (51yo)

    Vice President of Research & Development

    • Tenure: 2.3yrs
    • Compensation: US$291.45k
  • Sami Sassoun (52yo)

    Executive Officer

    • Tenure: 0.2yrs
    • Compensation: US$376.42k
  • Eran Hertz (47yo)

    Executive Officer

    • Tenure: 2.7yrs
    • Compensation: US$141.33k
  • David Podwalski (64yo)

    President

    • Tenure: 1yrs
    • Compensation: US$392.09k

Board Members

  • Revan Schwartz (73yo)

    Director

    • Tenure: 2.9yrs
    • Compensation: US$74.07k
  • Angela Strand (50yo)

    Vice Chairman of the Board

    • Tenure: 2.6yrs
    • Compensation: US$112.25k
  • Irl Hirsch

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs
  • Bob Fischell (90yo)

    Director

    • Tenure: 9.8yrs
    • Compensation: US$67.75k
  • Lutz Heinemann

    Chairman of Scientific & Clinical Advisory Board

    • Tenure: 0yrs
  • Avner Gal (65yo)

    Co-Founder

    • Tenure: 2.6yrs
    • Compensation: US$187.39k
  • David Podwalski (64yo)

    President

    • Tenure: 1yrs
    • Compensation: US$392.09k
  • Michael Heise

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs
  • Jan Bolinder

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0yrs
  • Shimon Rapps

    Director

    • Tenure: 0.3yrs

Company Information

Integrity Applications, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Integrity Applications, Inc.
  • Ticker: IGAP
  • Exchange: OTCPK
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$71.257m
  • Shares outstanding: 161.95m
  • Website: https://www.integrity-app.com

Number of Employees


Location

  • Integrity Applications, Inc.
  • 19 Ha'Yahalomim Street
  • PO Box 12163
  • Ashdod
  • 7760049
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IGAPOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 2013

Biography

Integrity Applications, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Europe a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 00:33
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.